PK-biomarker-safety modelling aids choice of recommended phase II dose and schedule for AZD6738 (ATR inhibitor)
Berges, A Cheung, A Pierce, A Dean, E Felicetti, B Standifer, N Smith, S Yates, J Lau, A Stephens, C
Berges, A
Cheung, A
Pierce, A
Dean, E
Felicetti, B
Standifer, N
Smith, S
Yates, J
Lau, A
Stephens, C
Citations
Altmetric:
Abstract
Description
Date
2018
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Berges A, Cheung SYA, Pierce AJ, Dean E, Felicetti B, Standifer N, et al. PK-biomarker-safety modelling aids choice of recommended phase II dose and schedule for AZD6738 (ATR inhibitor). Cancer Res. 2018;78(13).